Emisphere Post-PROTECT
Pursuing solid heparin oral formulation
- Significant cost savings due to suspension of PROTECT 2 and cancellation of programs related to liquid heparin product
Restructuring completed
- 30% reduction in work force principally related to liquid heparin program
- Experienced research and development teams related to core oral drug delivery technology remain intact
- No impact on other programs
- Emphasis on product-focused culture
Stronger Financial Position